# FDA approves atezolizumab and hyaluronidase-tqjs for subcutaneous injection

Source: [What's New: Drugs RSS Feed](http://www.fda.gov/drugs/cancer-approvals/fda-approves-atezolizumab-and-hyaluronidase-tqjs-subcutaneous-injection) · 2026-11-07 · Medicine
Page: https://themorning.science/story/fda-approves-atezolizumab-and-hyaluronidase-tqjs-for-subcutaneous-injection-fb5163c6506b94ce
Kind: launch · Impact: medium

## In brief

- The FDA approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech) for subcutaneous injection.
- The subcutaneous formulation covers all adult indications that the intravenous formulation of atezolizumab (Tecentriq) carries.
- The approval took place on September 12, 2024, according to the FDA announcement.

## Why it matters

Adult patients on atezolizumab treatment may now receive the drug by subcutaneous injection instead of intravenous infusion, which can change how and where treatment is given.

## Timeline

- 2024-09-12: FDA approves subcutaneous atezolizumab and hyaluronidase-tqjs

## Coverage

- [FDA approves atezolizumab and hyaluronidase-tqjs for subcutaneous injection](http://www.fda.gov/drugs/cancer-approvals/fda-approves-atezolizumab-and-hyaluronidase-tqjs-subcutaneous-injection) — What's New: Drugs RSS Feed, 2026-11-07

Tags: fda, atezolizumab, subcutaneous, oncology, drug-approval, genentech

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science